AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
INSULIN HUMAN
27 registrations across 7 African markets— 19 active
Markets with INSULIN HUMAN
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Actrapid® Flexpen 100 IU/ml (5 x 3ml) Solution For Injection | 🇰🇪Kenya | Novo Nordisk A/S | active | Apr 2031 |
| GENSULIN N SOLUTION; INJECTION | 🇿🇼Zimbabwe | COSPHARM INVESTMENTS PVT LTD | active | Oct 2030 |
| ACTRAPHANE FLEXPEN INJECTABLE; INJECTION | 🇿🇼Zimbabwe | NOVO NORDISK KENYA LIMITED | active | Dec 2027 |
| ACTRAPID FLEXPEN SOLUTION; INJECTION | 🇿🇼Zimbabwe | NOVO NORDISK KENYA LIMITED | active | Dec 2027 |
| PROTAPHANE FLEXPEN INJECTABLE; INJECTION | 🇿🇼Zimbabwe | NOVO NORDISK KENYA LIMITED | active | Dec 2027 |
| INSUMAN RAPID (300 IU/3 ML) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | suspended | Apr 2023 |
| INSUMAN BASAL (300 IU/3 ML) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | suspended | Jan 2023 |
| INSUMAN COMB 30/70 (1000 IU/10 ML) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | suspended | Feb 2022 |
| INSUMAN RAPID (1000 IU/10 ML) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | suspended | Feb 2022 |
| INSUMAN BASAL (1000 IU/10 ml) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | suspended | Feb 2022 |
| JUSLINE_30/70 100 UNITS/ML INJECTION INJECTION | 🇲🇼Malawi | — | expired | Jun 2017 |
| JUSLINE_N 100UNITS/ML INJECTION INJECTION | 🇲🇼Malawi | — | expired | Jun 2017 |
| JUSLINE_R 100 UNITS/ML INJECTION INJECTION | 🇲🇼Malawi | — | expired | Jun 2017 |
| INSUMAN COMB 30/70 (300 IU/3 ml) | 🇿🇦South Africa | Sanofi-Aventis South Africa (Pty) Ltd | active | Jan 1900 |
| DIABULYN N | 🇿🇦South Africa | Ascendis Pharma (Pty) Ltd | active | Jan 1900 |
| DIABULYN R | 🇿🇦South Africa | Ascendis Pharma (Pty) Ltd | active | Jan 1900 |
| Insulin Human Solution for injection 100IU/ml Solution for injection | 🌍WW | Novo Nordisk AS | active | — |
| Insulin Human Solution for injection 100IU/ml Solution for injection | 🌍WW | Novo Nordisk AS | active | — |
| INSULATARD FLEXPEN Injection | 🇹🇿Tanzania | Novo Nordisk A/S | active | — |
| MIXTARD 30 FLEXPEN Injection | 🇹🇿Tanzania | Novo Nordisk A/S | active | — |
| INSULIN HUMAN PARENTERAL
ORDINARY S C VIALS | 🇺🇬Uganda | NOVO NORDISK | active | — |
| INSULIN HUMAN PARENTERAL
ORDINARY S C
VIALS | 🇺🇬Uganda | NOVO NORDISK | active | — |
| ACTRAPID FLEXPEN Injection | 🇹🇿Tanzania | Novo Nordisk A/S | active | — |
| Insulin Human Suspension for injection 100IU/ml Suspension for injection | 🌍WW | Novo Nordisk AS | active | — |
| INSULIN HUMAN PARENTERAL
ORDINARY S C VIALS | 🇺🇬Uganda | NOVO NORDISK | active | — |
| Insulin Human Suspension for injection 100IU/ml Suspension for injection | 🌍WW | Novo Nordisk AS | active | — |
| INSULIN HUMAN PARENTERAL
ORDINARY S C
VIALS | 🇺🇬Uganda | NOVO NORDISK | active | — |
INSULIN HUMAN in Africa — Regulatory Overview
INSULIN HUMAN is registered across 7 African markets with 27 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Uganda, WW, Zimbabwe and 3 more. AfricaRegulatory refreshes this data daily from official government sources.
Of the 27 registrations, 19 (70%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.